Verkest et al. in their 2021 review discuss activators and inhibitors of TRESK, TREK-1, and TREK-2 as playing “a key role in [...] neuronal excitability,” recommending these channels as targets for migraine treatment. The gene discussed is KCNK2; the disease is migraine disorder.